In this paper, we have endeavored to examine whether the combination of a PI3K/mTOR inhibitor, NVP‐BEZ235, or an Akt ATP‐competitive inhibitor, AZD5363, could sensitize cancer cells to the cytocidal activity of cisplatin or doxorubicin. This evidence concerns the gene MTOR and cancer.